Co-administration of a caspase-1 inhibitor along with Ang II attenuated the thickening effect of the latter, which indicates that caspase-1-induced pyroptosis is closely related to cardiac hypertrophy and therefore a promising therapeutic target (Franchi et al., 2006). This evidence concerns the gene CASP1 and cardiac hypertrophy.